Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
161 shown of 6,613 total abstracts
  1. Abstract 10452026-06-05 · 13:00 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    E. Winer, J. Brahmer, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 13962026-06-03 · 15:15 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    C. Saura, F. Andre · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 16322026-06-04 · 15:30 CT · S100A
    MONARCH-589: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    F. Andre, C. Saura, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 14712026-06-04 · 21:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Brahmer, C. Robert · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 13942026-06-02 · 19:15 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-53
    T. Mok, H. Borghaei, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 19852026-06-05 · 15:15 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    J. Brahmer, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 13622026-06-03 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-259
    N. Rizvi, S. Antonia · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 19662026-06-05 · 19:00 CT · Hall B1
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-524
    S. Modi, R. Herbst, F. Andre, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 10662026-06-02 · 16:30 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-760
    L. Paz-Ares, J. Brahmer · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 13102026-06-04 · 18:45 CT · Arie Crown Theater
    MONALEESA-863: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    S. Peters, R. Herbst, J. Brahmer · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 18092026-06-02 · 21:00 CT · E450
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    G. Curigliano, L. Paz-Ares, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 10272026-06-02 · 15:15 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    J. Cortes, S. Modi, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 14752026-06-03 · 13:30 CT · E450
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-183
    S. Peters, N. Rizvi, E. Winer, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 12392026-06-01 · 20:30 CT · Hall B1
    PALOMA-822: Ibrance (palbociclib) maintenance in HR+ breast cancer
    G. Curigliano, H. Rugo, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 19712026-06-02 · 21:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-1
    H. Rugo, E. Winer, M. Reck · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 19502026-06-01 · 18:45 CT · S406
    PALOMA-375: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    C. Saura, S. Antonia · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 18452026-06-03 · 14:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-426
    M. Krop, J. Brahmer, H. Rugo · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 10302026-06-05 · 13:30 CT · E450
    KEYNOTE-433: Keytruda (pembrolizumab) 1L in TNBC
    C. Robert, L. Paz-Ares, F. Andre, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 16502026-06-02 · 16:30 CT · Arie Crown Theater
    IMpower-47: Tecentriq (atezolizumab) 2L in TNBC
    N. Rizvi, C. Robert, A. Spira, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 11532026-06-05 · 20:15 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-161
    J. Brahmer, C. Saura, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 16942026-06-04 · 21:30 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M. Krop, J. Brahmer · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 16452026-06-05 · 16:00 CT · Hall B1
    MONARCH-162: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Tolaney, C. Robert · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 15112026-06-04 · 15:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-337 study)
    G. Curigliano, S. Peters, C. Robert · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 14482026-06-02 · 18:15 CT · S406
    DESTINY-Breast-908: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    H. Rugo, S. Tolaney, C. Robert · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 17182026-06-05 · 20:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-792
    J. Brahmer, S. Antonia, H. Rugo, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 18672026-06-01 · 19:15 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-961
    S. Antonia, A. Spira, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 12242026-06-03 · 21:00 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-27
    H. Borghaei, S. Peters, M. Reck, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 15112026-06-04 · 13:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-389 study)
    S. Tolaney, P. Schmid, C. Saura · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  29. Abstract 17072026-06-02 · 21:30 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    S. Modi, S. Antonia · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 12592026-06-04 · 13:45 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    H. Rugo, A. Spira, M.C. Garassino, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 13332026-06-03 · 15:00 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-910
    T. Mok, C. Robert, N. Rizvi, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 12092026-06-05 · 19:45 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    C. Saura, S. Modi, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 10392026-06-01 · 20:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-33
    F. Andre, S. Peters, H. Borghaei · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 14352026-06-01 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-315 study)
    L. Paz-Ares, J. Cortes, S. Modi · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 17462026-06-01 · 16:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-314
    S. Modi, R. Herbst, T. Mok, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 13852026-06-03 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    M. Reck, C. Saura, A. Spira · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 18112026-06-01 · 14:45 CT · S100A
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-292
    R. Herbst, C. Saura, J. Cortes, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 18722026-06-01 · 15:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-373 study)
    J. Cortes, S. Peters, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 19152026-06-04 · 14:30 CT · E450
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-646
    S. Modi, S. Peters, E. Winer · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 19872026-06-04 · 15:00 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    N. Rizvi, S. Antonia, S. Modi, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 17772026-06-04 · 16:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-190 study)
    P. Schmid, T. Mok, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 18912026-06-03 · 20:00 CT · E450
    Quality of life outcomes with Tecentriq in patients with TNBC
    M. Krop, N. Rizvi · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 10162026-06-02 · 18:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-344
    G. Curigliano, C. Saura, M. Reck · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 17092026-06-05 · 14:45 CT · E450
    KEYNOTE-146: Keytruda (pembrolizumab) neoadjuvant in TNBC
    A. Spira, M. Reck, S. Modi, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 17072026-06-03 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-371 study)
    R. Herbst, G. Curigliano, F. Andre, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 14372026-06-04 · 13:45 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-303
    C. Robert, J. Cortes · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 14542026-06-02 · 16:30 CT · Arie Crown Theater
    MONARCH-393: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    C. Saura, M. Krop, G. Curigliano, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 17092026-06-04 · 21:45 CT · Hall B1
    MONARCH-734: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    M. Reck, G. Curigliano, T. Mok, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 15212026-06-03 · 20:00 CT · S100A
    ASCENT-329: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    R. Herbst, H. Rugo, E. Winer, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 10882026-06-04 · 16:45 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-641
    F. Andre, S. Modi, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 18722026-06-01 · 15:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-961
    R. Herbst, F. Andre, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 17502026-06-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-961 study)
    S. Tolaney, C. Robert, H. Rugo, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 10542026-06-03 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-515 study)
    C. Saura, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 15272026-06-04 · 21:00 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-550 study)
    T. Mok, G. Curigliano, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 16102026-06-01 · 16:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-878
    E. Winer, S. Modi · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 12212026-06-05 · 21:15 CT · Hall B1
    ASCENT-614: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    N. Rizvi, L. Paz-Ares, A. Spira, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 16072026-06-04 · 21:30 CT · E450
    MONARCH-382: Verzenio (abemaciclib) 1L in HR+ breast cancer
    J. Cortes, S. Modi, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 10272026-06-04 · 19:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-456
    S. Antonia, C. Robert, M. Reck, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 12742026-06-04 · 21:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-857
    S. Modi, G. Curigliano · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 14232026-06-03 · 14:45 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    S. Modi, J. Brahmer · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 12022026-06-04 · 16:00 CT · S100A
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-402
    N. Rizvi, C. Saura, T. Mok · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 12642026-06-01 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-972
    S. Tolaney, T. Mok · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 19432026-06-05 · 20:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-50
    M. Reck, T. Mok · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 11882026-06-05 · 18:00 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    J. Brahmer, H. Rugo, P. Schmid, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 19392026-06-02 · 15:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-685 study)
    H. Rugo, L. Paz-Ares, G. Curigliano, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 14582026-06-03 · 21:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-979 study)
    P. Schmid, S. Antonia · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 14622026-06-04 · 15:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-829
    C. Saura, J. Brahmer, A. Spira, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 17792026-06-02 · 19:45 CT · S100A
    MONALEESA-151: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    J. Brahmer, N. Rizvi, E. Winer · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 11152026-06-01 · 18:00 CT · S100A
    PALOMA-849: Ibrance (palbociclib) 2L in HR+ breast cancer
    S. Tolaney, H. Borghaei · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 17662026-06-04 · 16:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-740 study)
    J. Cortes, C. Saura, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  71. Abstract 19632026-06-03 · 15:00 CT · Hall B1
    MONALEESA-835: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    A. Spira, F. Andre, R. Herbst, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 12282026-06-02 · 14:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with TNBC
    J. Brahmer, L. Paz-Ares, S. Modi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 17772026-06-02 · 14:30 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-932 study)
    S. Modi, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 12992026-06-04 · 21:15 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-648 study)
    C. Saura, T. Mok · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  75. Abstract 18962026-06-05 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-994 study)
    C. Saura, S. Antonia · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 12562026-06-02 · 21:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-735 study)
    L. Paz-Ares, C. Saura, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  77. Abstract 10422026-06-03 · 16:45 CT · Hall B1
    MONALEESA-336: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Peters, G. Curigliano, C. Robert · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  78. Abstract 13982026-06-02 · 14:45 CT · E450
    OlympiA-512: Lynparza (olaparib) 3L+ in HR+ breast cancer
    S. Peters, M. Krop · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 18802026-06-01 · 13:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-881
    H. Borghaei, T. Mok, A. Spira · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  80. Abstract 11032026-06-01 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-273
    F. Andre, R. Herbst, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  81. Abstract 18192026-06-04 · 20:00 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-428 study)
    S. Modi, M.C. Garassino, H. Rugo, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  82. Abstract 14332026-06-02 · 19:00 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-472
    J. Brahmer, J. Cortes, H. Rugo · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  83. Abstract 15132026-06-05 · 19:45 CT · S406
    PALOMA-696: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    J. Cortes, E. Winer · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  84. Abstract 17822026-06-02 · 14:00 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-947
    M. Reck, R. Herbst, F. Andre, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  85. Abstract 17542026-06-02 · 20:15 CT · S100A
    IMpower-781: Tecentriq (atezolizumab) maintenance in TNBC
    C. Saura, T. Mok, M. Krop, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  86. Abstract 13662026-06-05 · 20:15 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-198
    M. Reck, P. Schmid, S. Antonia, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 18002026-06-03 · 20:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-694
    M.C. Garassino, S. Tolaney, S. Antonia · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 15492026-06-03 · 16:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-386 study)
    H. Borghaei, F. Andre, M.C. Garassino, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  89. Abstract 19522026-06-02 · 19:15 CT · Hall B1
    MONARCH-731: Verzenio (abemaciclib) 2L in HR+ breast cancer
    P. Schmid, H. Borghaei, E. Winer · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  90. Abstract 14682026-06-01 · 21:30 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-382
    M.C. Garassino, G. Curigliano, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  91. Abstract 11522026-06-03 · 16:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-572 study)
    S. Tolaney, M. Krop, H. Rugo · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  92. Abstract 16512026-06-02 · 15:15 CT · Hall B1
    MONALEESA-401: Kisqali (ribociclib) 2L in HR+ breast cancer
    C. Robert, G. Curigliano, S. Tolaney, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  93. Abstract 18682026-06-05 · 13:30 CT · S100A
    MONALEESA-118: Kisqali (ribociclib) 1L in HR+ breast cancer
    J. Cortes, H. Borghaei, F. Andre, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  94. Abstract 12072026-06-04 · 15:00 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-768
    S. Modi, C. Saura, M. Reck, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  95. Abstract 12322026-06-05 · 16:15 CT · S100A
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-828
    A. Spira, C. Saura, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 16352026-06-01 · 20:45 CT · S100A
    DESTINY-Breast-949: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    J. Brahmer, E. Winer, C. Saura, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 13332026-06-01 · 16:15 CT · S100A
    PALOMA-210: Ibrance (palbociclib) 1L in HR+ breast cancer
    C. Robert, S. Modi, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  98. Abstract 16742026-06-04 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-758 study)
    G. Curigliano, T. Mok, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  99. Abstract 14012026-06-03 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-906 study)
    L. Paz-Ares, P. Schmid, H. Rugo, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  100. Abstract 14992026-06-02 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-944 study)
    M.C. Garassino, A. Spira, G. Curigliano, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 17272026-06-04 · 19:45 CT · Arie Crown Theater
    ASCENT-134: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    A. Spira, M.C. Garassino, C. Robert, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  102. Abstract 13192026-06-05 · 14:45 CT · S406
    PALOMA-362: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    C. Robert, H. Rugo, S. Antonia · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  103. Abstract 18872026-06-01 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda maintenance for TNBC: KEYNOTE-476
    L. Paz-Ares, M.C. Garassino · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 11082026-06-01 · 20:00 CT · Arie Crown Theater
    DESTINY-Breast-822: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    H. Borghaei, S. Antonia, A. Spira, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  105. Abstract 13672026-06-02 · 13:30 CT · Arie Crown Theater
    ASCENT-620: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    C. Robert, F. Andre, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  106. Abstract 13082026-06-02 · 14:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-691 study)
    S. Antonia, T. Mok · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  107. Abstract 14522026-06-01 · 13:30 CT · S100A
    Long-term follow-up of Keytruda adjuvant for TNBC: KEYNOTE-486
    H. Rugo, M.C. Garassino, M. Krop, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 17802026-06-02 · 18:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-43
    S. Antonia, M.C. Garassino · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  109. Abstract 14172026-06-04 · 13:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-647
    G. Curigliano, S. Antonia, P. Schmid · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 11262026-06-02 · 16:15 CT · Arie Crown Theater
    MONARCH-974: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    S. Peters, S. Antonia, H. Borghaei, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  111. Abstract 14562026-06-05 · 16:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-153
    C. Robert, H. Rugo, M. Reck · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  112. Abstract 12742026-06-05 · 15:30 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-159
    J. Brahmer, R. Herbst, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 18242026-06-03 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-553
    L. Paz-Ares, M.C. Garassino, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 12312026-06-04 · 18:30 CT · E450
    OlympiA-825: Lynparza (olaparib) 3L+ in HR+ breast cancer
    E. Winer, G. Curigliano, R. Herbst, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  115. Abstract 14082026-06-03 · 14:45 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-444
    J. Brahmer, A. Spira, C. Robert, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 12652026-06-04 · 20:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-497 study)
    F. Andre, E. Winer, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 14602026-06-05 · 16:30 CT · E450
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-812
    F. Andre, C. Robert · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  118. Abstract 18602026-06-04 · 20:45 CT · E450
    OlympiA-187: Lynparza (olaparib) adjuvant in HR+ breast cancer
    J. Brahmer, M. Reck, S. Modi, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract 16862026-06-04 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-963 study)
    L. Paz-Ares, S. Tolaney, G. Curigliano, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 13872026-06-01 · 18:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-229
    N. Rizvi, M. Reck, A. Spira · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  121. Abstract 13562026-06-02 · 15:45 CT · E450
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-267
    H. Rugo, T. Mok · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 15082026-06-03 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-809
    S. Modi, N. Rizvi, H. Rugo, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 18102026-06-05 · 16:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-483
    H. Borghaei, S. Modi, J. Cortes, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  124. Abstract 17532026-06-02 · 15:45 CT · S406
    ASCENT-4: Trodelvy (sacituzumab govitecan) 2L in TNBC
    N. Rizvi, H. Borghaei, J. Brahmer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  125. Abstract 13092026-06-03 · 19:00 CT · E450
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-242
    T. Mok, H. Rugo · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  126. Abstract 19692026-06-01 · 21:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-283
    N. Rizvi, C. Saura, H. Rugo · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  127. Abstract 17602026-06-05 · 13:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-458 study)
    S. Antonia, M. Krop, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 15712026-06-01 · 21:45 CT · Hall B1
    PALOMA-244: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    T. Mok, S. Peters, S. Tolaney, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  129. Abstract 11772026-06-04 · 14:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-987 study)
    T. Mok, H. Borghaei, R. Herbst · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 19642026-06-04 · 18:45 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-781
    C. Saura, M. Krop, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  131. Abstract 13332026-06-05 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-768 study)
    F. Andre, H. Rugo, P. Schmid · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  132. Abstract 18262026-06-04 · 16:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-978
    E. Winer, F. Andre, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  133. Abstract 16842026-06-01 · 13:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-896
    E. Winer, R. Herbst, C. Robert · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 13902026-06-04 · 13:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-919
    S. Peters, C. Saura, E. Winer, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  135. Abstract 15582026-06-02 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-70 study)
    T. Mok, S. Tolaney, N. Rizvi, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  136. Abstract 17962026-06-02 · 15:15 CT · S406
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-747
    H. Borghaei, S. Tolaney, P. Schmid, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 10642026-06-05 · 18:30 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-126
    C. Saura, N. Rizvi, J. Brahmer, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 10472026-06-05 · 21:45 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-953
    S. Modi, N. Rizvi · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  139. Abstract 11182026-06-04 · 18:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-821
    P. Schmid, G. Curigliano · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  140. Abstract 17422026-06-02 · 21:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-721
    S. Modi, L. Paz-Ares, S. Peters · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  141. Abstract 10952026-06-03 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-867 study)
    C. Robert, H. Rugo · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  142. Abstract 14422026-06-04 · 18:15 CT · S406
    IMpower-864: Tecentriq (atezolizumab) adjuvant in TNBC
    M. Krop, M. Reck, T. Mok, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  143. Abstract 12572026-06-01 · 13:00 CT · Hall B1
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-708
    S. Modi, M.C. Garassino, J. Cortes · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract 16732026-06-03 · 13:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-349 study)
    L. Paz-Ares, M. Krop, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 17652026-06-02 · 14:30 CT · S406
    MONALEESA-171: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Krop, C. Robert, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 11342026-06-02 · 21:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-269
    E. Winer, H. Rugo, M.C. Garassino, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 13932026-06-01 · 13:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-411
    R. Herbst, M. Krop, T. Mok, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 15162026-06-04 · 18:45 CT · Hall B1
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-34
    S. Modi, M.C. Garassino, M. Krop, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  149. Abstract 16262026-06-01 · 16:00 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-721 study)
    L. Paz-Ares, M. Reck, P. Schmid · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 19442026-06-02 · 15:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-159 study)
    F. Andre, S. Antonia, A. Spira · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  151. Abstract 11082026-06-01 · 20:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-517 study)
    L. Paz-Ares, H. Rugo · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  152. Abstract 14852026-06-05 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-624
    F. Andre, R. Herbst, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  153. Abstract 11522026-06-01 · 15:00 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-407 study)
    N. Rizvi, S. Modi, C. Saura, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  154. Abstract 17242026-06-03 · 20:30 CT · E450
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-162
    H. Borghaei, G. Curigliano, C. Saura, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  155. Abstract 18872026-06-01 · 21:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-749
    R. Herbst, T. Mok · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  156. Abstract 18482026-06-01 · 21:30 CT · S100A
    MONARCH-633: Verzenio (abemaciclib) 2L in HR+ breast cancer
    F. Andre, M.C. Garassino, S. Antonia, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  157. Abstract 10762026-06-02 · 14:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-266
    R. Herbst, T. Mok, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  158. Abstract 15682026-06-03 · 20:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-359 study)
    S. Antonia, E. Winer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract 19762026-06-03 · 16:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-419
    L. Paz-Ares, H. Rugo, M. Krop, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  160. Abstract 18522026-06-04 · 15:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-604
    J. Brahmer, A. Spira, S. Tolaney, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  161. Abstract 13552026-06-01 · 15:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-462
    M. Reck, C. Saura · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.